Skip to main content

Myriad Expands Stock Repurchase Program

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics today said that its board of directors has authorized the repurchase of an additional $100 million of the firm's outstanding common stock.

The Salt Lake City-based molecular diagnostics firm already repurchased $100 million of its common stock under the initial repurchase program started this past May. It plans to repurchase the additional shares on the open market or through privately negotiated purchases and expects to complete the program by June 30, 2011.

"The expansion of our stock repurchase program reflects our confidence in the long-term potential for Myriad Genetics and our commitment to increasing shareholder value by returning capital to our shareholders," Myriad CFO James Evans said in a statement.

In early Tuesday trade on the Nasdaq, shares of Myriad were up 1 percent at $15.80.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.